• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kezar Life Sciences Inc (NQ: KZR )

    0.5701 -0.0049 (-0.85%)
    Streaming Delayed Price Updated: 11:46 AM EDT, Sep 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Kezar Life Sciences Inc

    < Previous 1 2 3 4 Next >
    Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
    Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases. 
    Via Benzinga
    KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
    KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
    KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
    Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries. 
    Via InvestorPlace
    Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
    Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology. 
    Via InvestorPlace
    KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
    KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Analyst Expectations for Kezar Life Sciences's Future
    Via Benzinga
    Kezar Life Sciences: Q1 Earnings Insights
    Via Benzinga
    Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
    Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
    Via Talk Markets
    3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
    When you want to light your afterburners, these ideas will do the trick. 
    Via InvestorPlace
    3 Penny Stocks Poised for an Unbelievable 1,000% Jump
    Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await. 
    Via InvestorPlace
    As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
    Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining. 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
    Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
    Via Benzinga
    Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
    Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
    Via Talk Markets
    Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
    Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Top 5 Health Care Stocks That Could Blast Off This Month
    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. 
    Via Benzinga
    Topics Bankruptcy
    Exposures Financial Legal
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      During Thursday, 56 stocks hit new 52-week lows. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
      On Tuesday, 56 companies set new 52-week lows. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
      On Monday, 76 companies set new 52-week lows. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Why Kezar Life Sciences Shares Are Volatile After Hours
    Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading higher in Monday's after-hours session after the company announced that it has received clearance of its Investigational New Drug (IND)... 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.